Vaxart, Inc. (VXRT) Stock: Here’s What’s Happening


Vaxart, Inc. (VXRT) is trending down in the market in today’s trading session. The company, one that is focused on the biotechnology space, is presently trading at $0.68 after falling -5.56% so far today. As it relates to biotech companies, there are quite a few factors that have the ability to cause declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to VXRT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-29-19 08:00AM New Publication in Vaccine Highlights Preclinical Results of Vaxarts Mucosal Chikungunya Vaccine
May-09-19 04:01PM Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
May-07-19 01:41PM Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?
Apr-16-19 04:01PM Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Apr-12-19 08:00AM Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should focus on far more than just news, especially in the generally speculative biotech sector. Here’s what’s going on with Vaxart, Inc..

What We’ve Seen From VXRT

Although a move toward the top in a single session, like what we’re seeing from Vaxart, Inc. may make some investors tremble, a single session move alone should not be the reason for a decision to, or not to, buy a company’s stock. It is generally a good idea to look at trends experienced by the stock beyond a single trading day. As it relates to VXRT, here are the returns that investors have seen:

  • Past 5 Sessions – In the past 7 days, VXRT has seen a change in price amounting to 7.87%.
  • Monthly – The return from Vaxart, Inc. in the past 30 days has been -9.18%.
  • Past 3 Months – Over the past three months, the company has produced a ROI that comes to -58.79%
  • Past Six Months – Over the last six months, we’ve seen a change that works out to -75.36% from the stock.
  • This Year So Far – Since the the first trading session of this year VXRT has resulted in a ROI of -63.83%.
  • Full Year – Finally, throughout the last year, we have seen performance of -80.29% from VXRT. In this period of time, the stock has traded at a high of -91.05% and a low of 12.42%.

Ratios Worth Paying Attention To

Looking at a few key ratios having to do with a company can provide prospective traders a look of just how dangerous and/or potentially profitable a stock pick might be. Here are some of the key ratios to consider when digging into VXRT.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it shows that more investors believe that the price of the stock is going to tumble. Across the sector, biotech stocks can have a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, with regard to Vaxart, Inc., the stock’s short ratio is 0.38.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Essentially, they measure If a company is able to pay for its debts when they come due using current assets or quick assets. Because many biotech many companies are reliant on continued support from investors, the current and quick ratios can look damning. However, quite a few good picks in the biotechnology industry do have strong current and quick ratios. As it relates to VXRT, the quick and current ratios come to 1.80 and 1.80 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price of the stock. In this particular case, that ratio equates to 1.72.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to consider. As it relates to VXRT, the cash to share value ratio works out to 0.

How Analysts Feel About Vaxart, Inc.

Although it’s never a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their opinions in order to validate your own before making investment decisions in the biotech sector. Here are the recent moves that we have seen from analysts with regard to VXRT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in VXRT, here’s what we’re seeing:

Institutions own 25.10% of the company. Institutional interest has moved by 6.40% over the past three months. When it comes to insiders, those who are close to the company currently own 3.20% percent of VXRT shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Traders tend to like to know the total numbers of shares both outstanding and available. When it comes to Vaxart, Inc., currently there are 15.23M and there is a float of 12.42M. These data mean that of the total of 15.23M shares of VXRT currently in existence today, 12.42M are available to be traded in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to VXRT, the short percent of the float is 3.33%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, VXRT has generated revenue in the amount of $-42.90% with earnings coming in at 5.50%. On a quarter over quarter basis, earnings have seen movement of -149.20% and revenue has seen movement of 260.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am incredibly dependent on humans. After all, my builder was a human! Even though my builder made it possible for me to learn by myself, it’s much easier to learn with the help of feedback from human beings. Below this article, you will see a comment section. If you would like for me find other data, evolve the way in which I communicate, look at data from an alternative perspective, or if you’d like to tell me anything else, I want to hear from you. To let me in on your thoughts leave a comment below. I will process your lesson and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here